| Title: | Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients |
|---|
| Authors: | ID Rehberger Likozar, Andreja (Author)
ID Ugovšek, Sabina (Author)
ID Šebeštjen, Miran (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,92 MB)
MD5: 9804FC28ED4DCA5D32373D31BA05FBB9
 URL - Source URL, visit https://www.sciencedirect.com/science/article/pii/S001429992300746X?via%3Dihub
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Despite progress in treatment, elevated levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) (Lp(a)), represent a significant part of the residual risk. Both are associated with inflammation and the coagulation fibrinolytic system. The purpose of our research was to evaluate the effect of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) on lipid parameters and indicators of inflammation, coagulation and fibrinolysis. We included 100 post myocardial infarction (MI) patients with insufficiently controlled LDL-C values despite the maximum dose of statin, and highly elevated Lp(a). Patients received alirocumab or evolocumab (150 mg sc or 140 mg sc every two weeks, respectively), or placebo for 6 months. In patients receiving PCSK9i, a significant decrease in total cholesterol (TC), LDL-C, triglycerides (TG) and Lp(a), and an increase in high density lipoprotein cholesterol (p < 0.001 for all) was found. Before treatment, the concentrations of TC, LDL-C and TG correlated with the concentrations of thrombin activatable fibrinolysis inhibitor (r = 0.41, p < 0.001; r = 0.353, p < 0.001; r = 0.311, p = 0.003, respectively), and plasminogen activator inhibitor-1 (r = 0.302, p = 0.007; r = 0.218, p = 0.049; r = 0.278; p = 0.013, respectively). The concentrations of TC and LDL-C correlated with overall fibrinolytic potential (r = −0.220, p = 0.034; r = −0.207, p = 0.047, respectively). The concentration of TG was related to the concentration of interleukin 6 (r = 0.290, p = 0.004) and interleukin 8 (r = 0.332, p = 0.001). No correlations between Lp(a) and inflammatory or hemostatic variables were found. No associations were found after treatment. Our results show that inflammatory cytokines and fibrinolytic parameters are related to LDL-C and not Lp(a) in post-MI patients before and with neither of them following PCSK9i treatment. |
|---|
| Keywords: | inflammation, hemostasis, PCSK9 inhibitors, LDL cholesterol, lipoprotein (a) |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 1-8 |
|---|
| Numbering: | Vol. 963, iss. [article no.] 176232 |
|---|
| PID: | 20.500.12556/DiRROS-29837  |
|---|
| UDC: | 616-002 |
|---|
| ISSN on article: | 0014-2999 |
|---|
| DOI: | 10.1016/j.ejphar.2023.176232 |
|---|
| COBISS.SI-ID: | 179035139 |
|---|
| Publication date in DiRROS: | 08.06.2026 |
|---|
| Views: | 170 |
|---|
| Downloads: | 162 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
